Trials / Unknown
UnknownNCT04818918
Coronary Flow and Myocardial Viability: the FloVITA Study
Study of the Relationship Between Coronary Flow and Myocardial Viability: the Single-centre, Observational, Prospective FloVITA Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of fractional flow reserve (FFR) is a key method for assessing ischemia with a view to guiding revascularization strategy following acute coronary syndrome. A stenosis that appears to be severe by angiography may cause limited ischemia (with an FFR value \>0.80) due to the incapacity of the necrotic zone to achieve physiological hyperemia, i.e. maximal coronary flow. Recently, it has been demonstrated that absolute coronary flow, and micro- and macrovascular resistance, as measured by a thermodilution technique, using the Rayflow microcatheter (Hexacath) are strongly associated with myocardial mass. In extensive necrosis, there is a loss of myocardial mass, and these tools could be of potential interest in measuring myocardial viability, which reflects the extent of remaining viable myocardial mass. Therefore, this study aims to investigate the relationship between both absolute coronary flow and microvascular resistance, and myocardial viability assessed by MRI. In a prospective, single-centre, interventional study, we will compare absolute coronary flow and microvascular resistance in the left anterior descending artery, in patients with and without a history of ST segment elevation MI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Absolute coronary flow measurement | Absolute coronary flow will be measured. |
| DEVICE | Microvascular resistance measurement | Microvascular resistance will be measured. |
| OTHER | Cardiac MRI | Cardiac MRI will be performed to evaluate myocardial viability. |
Timeline
- Start date
- 2021-05-19
- Primary completion
- 2024-08-20
- Completion
- 2024-08-20
- First posted
- 2021-03-26
- Last updated
- 2024-02-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04818918. Inclusion in this directory is not an endorsement.